Physician profile
Kari Rischling
NPI 1013323922
$2,140.83
in general payments reported to CMS, 2019-2025
24 companies · $633 in 2025
The $633 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.01 · 2023: $686 · 2024: $795 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.86 | 2023-2025 | |
| Novo Nordisk INC | $241.19 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $223.75 | 2023-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Lilly USA, LLC | $220.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $155.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $90.31 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.07 | 2023-2025 | Jardiance |
| Axsome Therapeutics, INC. | $76.46 | 2024-2025 | Auvelity |
| Abbott Laboratories | $65.48 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $50.41 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $46.39 | 2025 | Spravato |
| Dexcom, INC. | $45.79 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $43.65 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.70 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $34.12 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $33.54 | 2024-2025 | Vyepti |
| Tonix Medicines, INC. | $21.85 | 2025 | Tonmya |
| Vanda Pharmaceuticals INC. | $20.39 | 2025 | Fanapt |
| Astellas Pharma US INC | $20.05 | 2024 | Veozah |
| Tris Pharma INC | $19.38 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $17.78 | 2023 | Rotateq, Vaxelis, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2023 | |
| Dynavax Technologies Corporation | $11.58 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $8.51 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Rischling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.